Shows / BioSpace
BioSpace
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
Episodes
BioSpaceBonus: Q1 2026 Job Market Update
Listen to BioSpace’s Vice President of Marketing Chantal Dresner and Careers Editor Angela Gabriel discuss 2026 job market performance so far, sharing the…
BioSpaceAutomation, Collaboration and the Future of Advanced Therapies
In this episode of Denatured, you'll listen to Jason Jones, head of global business development at Cellular Origins and Alexander Seyf, founder & CEO of…
BioSpaceLilly’s Foundayo Nod Launches New Battle With Novo, M&A Mania Continues, Tariffs Hit Pharma
Eli Lilly won FDA approval last week for orforglipron—now Foundayo— officially launching what promises to be a heated battle between Lilly and chief rival Novo…
BioSpaceThe Radiotherapeutics Moment: How Isotopes are Changing Cancer Treatment
In this episode of Denatured, you'll listen to Dr. Marc Hedrick, President and CEO of Plus Therapeutics and Dr. Phil Kantoff, CEO & Co-founder of Convergent…
BioSpaceBiopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes
Biogen, Eli Lilly and Merck spent more than $20 billion in the past week to swallow biotechs with approved products or promising drug candidates—representing…
BioSpaceBeyond Buzzwords in Longevity Investing
In this episode, you'll be listening to Sergey Jakimov, managing partner at LongeVC and Artem Trotsyuk, operating partner, US, LongeVC. We discuss how…
BioSpaceGilead’s Ouro Buy, J&J/Protagonist’s Approval, Aurinia’s Revamp, ACIP Confusion, More
Immunology & inflammation stole the show this week, as Gilead dropped up to $2.1 billion for Ouro Medicines and its T cell engager OM336—an investment it hopes…
BioSpaceInside the Race to Build the Next Generation of AI Drug Discovery Platforms
In this episode, you'll be listening to Akshay Rai, principal, Healthcare & Biotech Investments at Premji Invest and Viswa Colluru, CEO and founder, Enveda…
BioSpaceKennedy’s Vaccine Agenda Stalled, Structure’s ‘Competitive’ Obesity Pill, Novo’s Warning Letter
Biopharma’s weight loss warriors have led the news this week, with Structure Therapeutics and Rhythm Pharmaceuticals announcing new data. Structure delivered a…
BioSpaceFrom Two Trials to One, Sponsors Face a Higher Standard
In this episode of Denatured, you'll listen to Oxana Iliach, senior director of regulatory strategy at Certara and Vera Pomerantseva, director of product…
BioSpacePrasad Out at FDA, Lawmaker Takes Action on Rare Disease Rejections and a Spate of Obesity Data
After Friday’s news that Center for Biologics Evaluation & Research Chief Vinay Prasad will leave the FDA—again—at the end of April, stocks for several rare…
BioSpaceRising Amid Flurry of CAR T Deals, Stylus Proves Cell Therapy Is Not Dead
Stylus Medicine CEO Emile Nuwaysir and Chief Scientific Officer Jason Fontenot speak with BioSpace about the biotech's work on next-generation genetic…
BioSpaceFrom Grants to Family Offices: Building a Unified Financing Strategy in Biotech
In this Denatured episode, Jennifer C. Smith-Parker speaks to Ram May-Ron, managing partner at FreeMind Group, and Ravi Kiron, managing director at Biopharma…
BioSpaceUniQure’s Delay, REGENXBIO’s Rejection Explained, Sarepta’s Ingram Steps Down, More
The FDA is dominating the headlines once again thisweek. Days after FDA Commissioner Marty Makary appeared to question uniQure’s gene therapy candidate for…
BioSpaceALS Advances Unite Patients and Pharma on Novel Targets, Biomarker Breakthroughs
In this episode, you'll be listening to Indu Navar, CEO and founder of EverythingALS and Dr. Olga Uspenskaya, chief medical officer at VectorY Therapeutics…
BioSpaceLilly Bests Novo Again, Rare Disease Week Goes Regulatory, More CDC Leadership Upheaval
Eli Lilly notches another win over Novo Nordisk, as Zepbound bests CagriSema in a head-to-head trial sponsored by Novo; The FDA kicked off Rare Disease Week…
BioSpaceCorsera Eyes Two-Pronged Approach To Tackle Leading Cardiovascular Killer
Corsera Health’s Chief Operating Officer Rena Denoncourt and CFO Meredith Kaya speak with BioSpace about the biotech’s mission and vision for the next…
BioSpaceRedefining Obesity Treatment Beyond GLP-1 Limits
In this episode, you'll be listening to Jane Hughes, President of R&D and Co Founder of Verdiva Bio, and Jon Rees, CEO and cofounder of MitoRx Therapeutics…
BioSpaceModernagate Fallout, Disc’s Rejection, Compass’ Psilocybin Data, CDC’s Lost Leaders
Last week, the FDA declined to review Moderna’s mRNA-based flu vaccine, with Center for Biologics Evaluation and Research Director Vinay Prasad himself signing…
BioSpaceAs FDA Moves Away From Animal Testing, AI and Organoids Can Shine
Last year, the FDA announced it would be phasingout animal testing requirements for some therapies. The NIHfollowed suit. According to Thomas Hartung…
BioSpaceDigital Pathology, AI and the Future of ADCs and HER2 Cancer Treatment
In this episode of Denatured, Jennifer C. Smith-Parker speaks with Dr. Rob Monroe, Vice President and Chief Scientific Officer of Oncology at Danaher…
BioSpaceWeight Loss Drama Compounds on Heels of Novo, Lilly Earnings, Plus Gene Therapy News
Last Thursday, Hims & Hers launched a compounded versionof Novo’s oral Wegovy, approved just before Christmas and launched in early January. Novo was, not…
BioSpaceProgrammable RNA 2.0: Beyond the First mRNA Revolution
In this episode of Denatured, Jennifer C. Smith-Parker speaks to Erik Digman Wiklud, CEO of Circio and Jacob Becraft, CO-founder and CEO of Strand…
BioSpacePfizer’s Metsera Data, 2025 Earnings, the FDA and REGENXBIO, Psychedelics and IPOs
Pfizer reported the first data from its new obesity pipeline, picked up in the nearly $10 billion acquisition of Metsera last fall. While BMO Capital Markets…
BioSpaceBiotech’s New Cycle, JPM Deal Hype and Where Alpha Still Hides
In this episode of Denatured, Jennifer C. Smith-Parker speaks with RTW’s Rod Wong and Stephanie Sirota how shifting JPM deal timing masks record M&A potential…
BioSpaceRoche Makes Obesity Splash, Moderna Cans Vaccine Trials, Sarepta’s New Data, More
Roche made the biggest splash this week so far, announcing on Tuesday that GLP-1/GIP injectable CT-388 led to 22.5%weight loss in a Phase II trial. These…
BioSpaceFrom Sound Bites to Signals: Editors Parse Executive and Investor Chatter at JPM
In this episode of Denatured, BioSpace editorial team members, Senior Editor, Annalee Armstrong, and News Editor, Dan Samorodnitsky, discuss their post-JPM…
BioSpaceJPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return
The 2026 J.P. Morgan Healthcare Conference concludedlast week without a big M&A deal. But the meeting was anything but boring, with President Donald…
BioSpaceBonus: Q4 2025 Job Market Update
In this episode, BioSpace’s Vice President of Marketing Chantal Dresner and Careers Editor Angela Gabriel discuss Q4 2025 job market performance, sharing the…
BioSpaceDeals Roll at JPM26, Policy Front and Center, IPOs Are Back, FDA Stays Busy
AbbVie bet nearly $5 billion for the ex-China rights to RemeGen’s PD-1/VEGF bispecific and Novartis struck a $1.5 billion Alzheimer’s-focused deal with…
BioSpaceFrom Nuclear Winter to Renewal: Biotech Investing for 2026
In this episode of Denatured, Jennifer C. Smith-Parker speaks to Maha Katabi, general partner at Sofinnova Investments and Andrew Lam, managing director, head…
BioSpaceNovo Launches Oral Obesity Pill, Lilly Targets Lofty Revenue, FDA and M&A in Focus
Obesity titans Novo Nordisk and Eli Lilly characteristically kicked off 2026 in the headlines. After capping 2025 with the first-ever FDA approval of an oral…
BioSpaceInside the 2026 Biotech Landscape: Innovation, Investment and Global Momentum
In this episode of Denatured, Jennifer Smith-Parker speaks to Kenneth Galbraith, CEO at Zymeworks and Josh Smiley, president and COO at Zai Lab, about how…
BioSpaceLilly’s Triple Triumph, Prasad’s COVID Error, J&J’s Surprise Voucher, M&A Targets
Eli Lilly is wrapping up 2025 with record-breaking weight loss in a late-stage trial for its triple hormone receptor agonist retatrutide. Results from the…
BioSpaceBeyond the Gluten-Free Diet: A New Era in Celiac Disease Treatment
In this episode presented by AnaptysBio, Jennifer Smith-Parker speaks to Dr. Joe Murray, professor of medicine, Division of Gastroenterology and Hepatology…
BioSpaceWeight Loss Waves, Pazdur’s Exit and FDA Instability, New Neuro Breakthroughs
Pfizer followed up its winning $10 billion bid forobesity startup Metsera by adding another molecule to its obesity cabinet, thisone from Chinese firm…
BioSpaceNew Approach Methodologies: Redefining Animal Testing Alternatives
Momentum is building behind New Approach Methodologies (NAMs) that offer stronger human relevance than traditional animal testing. The FDA issued on December 2…
BioSpacePrasad’s Leaked FDA Memo, Alzheimer’s Ups and Downs, Next-Gen Obesity Drugs
Vinay Prasad’s memo, leaked over the weekend, has sent vaccine makers’ stocks slipping and experts clamoring for more evidence to support the CBER director’s…
BioSpaceBillions More in M&A, Another Bidding War and More FDA Drama
Acquisitions have ticked up this month as all eyes were on Pfizer and Novo’s fight over Metsera. The past week saw that deal finalized with Pfizer as the…
BioSpaceHow Biotech Funding is Changing Executive Search and Hiring Processes
A lean funding environment has changed how biotechs approach workforce organization and executive hiring. Searches are becoming more targeted and intentional…
BioSpacePfizer Wins Metsera, Trump Strikes GLP-1 Pricing Deal, FDA Awards More Priority Vouchers
One of biopharma’s most memorable bidding wars finally came to an end on Friday—with Metsera right back in the arms of its original suitor, but with Pfizer…
BioSpaceThoughtful Tech: How Removing Technological Burdens Can Improve Clinical Trial Compliance and Patient Experience
This conversation features insights from Oliver Eden, senior business unit director at Jabil, and Travis Webb, chief scientific officer at PII. Our guests…
BioSpacePfizer and Novo Battle Over Metsera, Tidmarsh Fights FDA Exit, UniQure and Sarepta Face Setbacks
Many of the top stories of 2025 are currently being written. We’re on the edge of our keyboards, watching and waiting as Pfizer and Novo Nordisk duke it out…
BioSpaceInnovation, Resilience, and the Future of Global Manufacturing
In this episode of Denatured, guests Dr. Jihye Jang-Lee and Dr. Khanh Courtney discuss how China, historically focused on manufacturing, is increasingly…
BioSpaceNovartis’ Big Buy, Q3 Earnings, Regeneron’s Dropped Cell Therapy, More
Novartis started the week early with a Sunday afternoon announcement of the acquisition of neuromuscular drug developer Avidity Biosciences for $12B. That’s…
BioSpaceHow Supply Chain Turbulence is Reshaping Biotech Strategy
In this episode of Denatured, guests Dr. Jihye Jang-Lee and Dr. Khanh Courtney how in light of economic uncertainty, small biotechs can turn to international…
BioSpaceNovo Board Upended, ESMO Excitement, FDA Awards, Replimune’s U-Turn
Novo Nordisk dominated the news cycle this week, with more leadership changes as the Novo Foundation replaced the company’s board, which will now be headed by…
BioSpaceCost Control to Capability Building: Rethinking Supply and Strategy in Pharma
In this episode of Denatured, guests Dr. Jihye Jang-Lee and Dr. Khanh Courtney will explore how healthcare and pharmaceutical players — from hospitals and…
BioSpaceWork Smart, Build Trust: Connecting Technology, Patient Compliance and Data Processing
This episode continues the discussion with Oliver Eden, senior business unit director at Jabil, and Travis Webb, chief scientific officer at PII, as they dive…
BioSpaceQ3 Earnings Are Here, Novo Ditches Cell Therapy but Buys Akero, Gov’t Shutdown Hits CDC
Johnson & Johnson kicked off Q3 earnings season on Tuesday with the announcement that it is splitting its orthopedics and medtech operations and that it has…
BioSpaceBonus: Q3 2025 Job Market Update
In this discussion, BioSpace’s vice president of marketing Chantal Dresner and careers editor Angela Gabriel take a look at job market performance in…
BioSpaceShutdown Pauses New Drug Reviews, CDC Issues New COVID Guidance, CGT Meets on Mesa
The U.S. government is now in its second week of a shutdown—with the FDA having paused acceptance of all new drug applications for the duration. But it was…
BioSpaceHit Me With Your Best Shot: Understanding Autoinjectors and Combination Drug Delivery Systems
Clinical trials can present many challenges for patients–particularly injections. Oliver Eden, senior business unit director at Jabil, and Travis Webb, chief…
BioSpaceM&A Picks Up, Walmsley Moves On, Pfizer’s MFN Deal and Hope for Huntington’s
Genmab closed out a busy third quarter for M&A in biopharma, picking up cancer biotech Merus for $8 billion. This deal—the year’s fifth largest—came just a…
BioSpaceFDA’s Autism Endeavor, Pfizer’s Obesity Comeback Bid, Psychedelics Revival, ACIP Confusion, More
The FDA is working to reapprove GSK’s long-dormant drug Wellcovorin (leucovorin) for cerebral folate deficiency, which the agency linked to “developmental…
BioSpaceWhat Do AI and Hammers Have in Common?
In this episode, Lori Ellis and Colin Zick spend a little time further discussing some of the points brought up in the Bioprocessing Summit last month. AI is a…
BioSpaceChina Crackdown, UK Exit, Novo Layoffs, Adcomm Flip Flop, More
A global shift may be underway in biopharma as the White House prepares legislation that would would place restrictions on drugs brought to the U.S. from…
BioSpaceUnpacking the Latest MAHA Report, RFK’s Senate Appearance, FDA’s CRL Drop and More
The Make America Healthy Again Commission released itssecond report Tuesday, recommending, among other efforts, an investigation into a possible link between…
BioSpaceThe 'Research Safety Net' Saving Scientists from Funding Crisis
In this episode, Mike Garrett, CEO of Taconic Biosciences, discusses how preclinical research companies are helping drug developers navigate the current…
BioSpaceCDC Faces Critical Meetings Amid COVID Vaccine Uncertainty, Plus Deals, FDA Approvals, More
We returned from the Labor Day holiday to a spate of intriguing deals, including two that could surpass $2 billion: Vertex’s new pact with Enlaza for…